Azithromycin in the extremely low birth weight infant for the prevention of Bronchopulmonary Dysplasia: A pilot study

Nursing and Health Professions

• Pilot Study 100%
• Prevention 100%
• Lung Dysplasia 100%
• Extremely Low Birth Weight 100%
• Azithromycin 100%
• Infant 57%
• Incidence 57%
• Placebo 57%
• Mortality 42%
• Steroids 42%
• Morbidity 28%
• Prematurity 28%
• Birth Weight 28%
• Group Therapy 28%
• Artificial Respiration 28%
• Oxygen 28%
• Inflammation 14%
• Procedures 14%
• Patient 14%
• Lung Disease 14%
• Neonatal Intensive Care Unit 14%
• Gestational Age 14%
• Intention to Treat Analysis 14%
• Prophylaxis 14%
• Patient Referral 14%
• Analysis of Variance 14%
• Cystic Fibrosis 14%
• Side Effect 14%
• Disease 14%
• Fibrosis 14%
• Pneumonia 14%

Medicine and Dentistry

• Azithromycin 100%
• Lung Dysplasia 100%
• Extremely Low Birth Weight 100%
• Incidence 57%
• Infant 57%
• Placebo 57%
• Mortality 42%
• Steroids 42%
• Therapeutic Procedure 28%
• Prematurity 28%
• Morbidity 28%
• Artificial Respiration 28%
• Group Therapy 28%
• Birth Weight 28%
• Development 14%
• Diseases 14%
• Patient Referral 14%
• Patient 14%
• Childbirth 14%
• Fibrosis 14%
• Oxygen Consumption 14%
• Pregnancy 14%
• Prophylaxis 14%
• Pneumonia 14%
• Oxygen 14%
• Silo-Filler's Disease 14%
• Neonatal Intensive Care Unit 14%
• Cystic Fibrosis 14%
• Gestational Age 14%
• Analysis of Variance 14%
• Intention-to-Treat Analysis 14%
• Inflammation 14%
• Diffuse Panbronchiolitis 14%
• Side Effect 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Lung Dysplasia 100%
• Extremely Low Birth Weight 100%
• Azithromycin 100%
• Incidence 57%
• Placebo 57%
• Mortality 42%
• Steroids 42%
• Morbidity 28%
• Prematurity 28%
• Oxygen 28%
• Side Effect 14%
• Cystic Fibrosis 14%
• Lung Disease 14%
• Disease 14%
• Inflammation 14%
• Fibrosis 14%
• Pneumonia 14%